Related Experiment Video
Updated: May 6, 2026

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
Published on: January 31, 2020
Efficacy of Telitacicept in treating IgA vasculitis nephritis: a two-case report
Shuang-Xi Li1, Rui-Kang Hu2, De-Liang Kong1
1Department of Nephrology, Changhai Hospital, The Naval Medical University, Shanghai, China.
Abstract:
Telitacicept, a B lymphocyte stimulator/A proliferation-inducing ligand dual-target fusion protein, mainly used for IgA nephropathy and systemic lupus erythematosus. We present two cases where adult patients with IgA vasculitis (IgAV) nephritis were successfully treated with Telitacicept, experienced no adverse reactions during the follow-up. Therefore, Telitacicept represents a promising additional treatment option for patients suffering from IgA vasculitis (IgAV).
More Related Videos
14:18Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
Published on: October 13, 2023
11:32Real-Time, High-Throughput Microscopic Quantification of Human Neutrophil Extracellular Trap Release and Assessing the Pharmacology of Antagonists
Published on: October 18, 2024
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Acute Pyelonephritis II: Diagnostic Studies and Management
Nephrotic Syndrome II : Assessment and Medical Management